State of the Science Summit on Breast Cancer | Conference

Dr. Kwa on the Potential Impact of Biosimilars in Oncology

June 27th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the potential impact of biosimilars in oncology.

Dr. Esteva Discusses Adjuvant Trastuzumab in HER2+ Breast Cancer

June 27th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses adjuvant trastuzumab (Herceptin) in HER2-positive early breast cancer.

Dr. Novik on the Adoption of Biosimilars in Breast Cancer

June 23rd 2018

Yelena Novik, MD, associate professor, Department of Medicine, New York University’s Perlmutter Cancer Center, discusses the adoption of biosimilars in breast cancer.

Dr. Majure on Unmet Needs for Patients With TNBC

November 8th 2017

Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).

Dr. Rugo on Hormone Therapy for Patients With Breast Cancer

November 7th 2017

Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.

Dr. Melisko on the Role of Neoadjuvant Chemotherapy in ER+ Cancer

October 27th 2017

Michelle E. Melisko, MD, a clinical professor of medicine, University of California, San Francisco (UCSF), discusses the role of neoadjuvant chemotherapy in estrogen receptor (ER)-positive breast cancer.

CDK4/6 Inhibitors Revolutionize Hormone-Positive Breast Cancer Care

October 27th 2017

Denise A. Yardley, MD, discusses the promise of CDK4/6 inhibitors in estrogen receptor–positive breast cancer, and the potential with immunotherapy agents.

Dr. Yardley on Current Recommendations for ER+ Breast Cancer Treatment

October 26th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

Hamilton Highlights Progress in HER2-Positive Breast Cancer

October 25th 2017

Erika P. Hamilton, MD, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Dr. Burris on the Potential of PARP Inhibitors in TNBC

October 24th 2017

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).

Dr. Hamilton on Extended Adjuvant Therapy for HER2+ Breast Cancer

October 16th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the role of extended adjuvant therapy for patients with HER2-positive breast cancer.

Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

October 8th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.